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Abstract: 
Neuropathic pain is a chronic neurological disorder affecting millions of people around the world. 
The currently available pharmacologic agents for the treatment of neuropathic pain have limited 
efficacy and are associated with dose related unwanted adverse effects. Due to the limited 
access of drug molecules across blood-brain barrier, a small percentage of drug that is 
administered systematically, reaches the central nervous system in active form. These 
therapeutic agents also require daily treatment regimen that is inconvenient and potentially 
impact patient compliance. Application of nanoparticulate drugs for enhanced delivery system 
has been explored extensively in the last decades. Pulmonary delivery of nanomedicines for the 
management of various diseases has become an emerging treatment strategy that ensures the 
targeted delivery of drugs both for systemic and local effects with low dose and limited adverse 
effects. To the best of our knowledge, there are no inhaled drug products available on market for 
the treatment of neuropathic pain. The advantages of delivering therapeutics into deep lungs 
include non-invasive drug delivery, higher bioavailability with low dose, lower systemic toxicity, 
and potentially greater blood-brain barrier penetration. This review discusses and highlights the 
important issues on the application of emerging nanoparticulate lung delivery of drugs for the 
effective treatment of neuropathic pain. 
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